Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 105

1.

Molecular and functional interaction between GPR18 and cannabinoid CB2 G-protein-coupled receptors. Relevance in neurodegenerative diseases.

Reyes-Resina I, Navarro G, Aguinaga D, Canela EI, Schoeder CT, Załuski M, Kieć-Kononowicz K, Saura CA, Müller CE, Franco R.

Biochem Pharmacol. 2018 Jun 2. pii: S0006-2952(18)30209-0. doi: 10.1016/j.bcp.2018.06.001. [Epub ahead of print]

PMID:
29870711
2.

Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer.

Dickler MN, Saura C, Richards DA, Krop IE, Cervantes A, Bedard PL, Patel MR, Pusztai L, Oliveira M, Cardenas AK, Cui N, Wilson TR, Stout TJ, Wei MC, Hsu JY, Baselga J.

Clin Cancer Res. 2018 Sep 15;24(18):4380-4387. doi: 10.1158/1078-0432.CCR-18-0613. Epub 2018 May 23.

PMID:
29793946
3.

Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases.

De Mattos-Arruda L, Ng CKY, Piscuoglio S, Gonzalez-Cao M, Lim RS, De Filippo MR, Fusco N, Schultheis AM, Ortiz C, Viteri S, Arias A, Macedo GS, Oliveira M, Gomez P, Teixidó C, Nuciforo P, Peg V, Saura C, Ramon Y Cajal S, Casas FT, Weigelt B, Cortes J, Seoane J, Reis-Filho JS.

Oncotarget. 2018 Apr 17;9(29):20617-20630. doi: 10.18632/oncotarget.25041. eCollection 2018 Apr 17.

4.

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.

Mattos-Arruda L, Weigelt B, Cortes J, Won HH, Ng CKY, Nuciforo P, Bidard FC, Aura C, Saura C, Peg V, Piscuoglio S, Oliveira M, Smolders Y, Patel P, Norton L, Tabernero J, Berger MF, Seoane J, Reis-Filho JS.

Ann Oncol. 2018 Apr 30. doi: 10.1093/annonc/mdx804. [Epub ahead of print] No abstract available.

PMID:
29718117
5.

Reversal of memory and neuropsychiatric symptoms and reduced tau pathology by selenium in 3xTg-AD mice.

Van der Jeugd A, Parra-Damas A, Baeta-Corral R, Soto-Faguás CM, Ahmed T, LaFerla FM, Giménez-Llort L, D'Hooge R, Saura CA.

Sci Rep. 2018 Apr 24;8(1):6431. doi: 10.1038/s41598-018-24741-0.

6.

Publisher Correction: MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer.

Gawrzak S, Rinaldi L, Gregorio S, Arenas EJ, Salvador F, Urosevic J, Figueras-Puig C, Rojo F, Del Barco Barrantes I, Cejalvo JM, Palafox M, Guiu M, Berenguer-Llergo A, Symeonidi A, Bellmunt A, Kalafatovic D, Arnal-Estapé A, Fernández E, Müllauer B, Groeneveld R, Slobodnyuk K, Stephan-Otto Attolini C, Saura C, Arribas J, Cortes J, Rovira A, Muñoz M, Lluch A, Serra V, Albanell J, Prat A, Nebreda AR, Benitah SA, Gomis RR.

Nat Cell Biol. 2018 Aug;20(8):990. doi: 10.1038/s41556-018-0052-0.

PMID:
29674681
7.

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.

Cruz C, Castroviejo-Bermejo M, Gutiérrez-Enríquez S, Llop-Guevara A, Ibrahim YH, Gris-Oliver A, Bonache S, Morancho B, Bruna A, Rueda OM, Lai Z, Polanska UM, Jones GN, Kristel P, de Bustos L, Guzman M, Rodríguez O, Grueso J, Montalban G, Caratú G, Mancuso F, Fasani R, Jiménez J, Howat WJ, Dougherty B, Vivancos A, Nuciforo P, Serres-Créixams X, Rubio IT, Oaknin A, Cadogan E, Barrett JC, Caldas C, Baselga J, Saura C, Cortés J, Arribas J, Jonkers J, Díez O, O'Connor MJ, Balmaña J, Serra V.

Ann Oncol. 2018 May 1;29(5):1203-1210. doi: 10.1093/annonc/mdy099.

8.

HER2-positive breast cancer: Current and new therapeutic strategies.

Escrivá-de-Romaní S, Arumí M, Bellet M, Saura C.

Breast. 2018 Jun;39:80-88. doi: 10.1016/j.breast.2018.03.006. Epub 2018 Apr 6.

PMID:
29631097
9.

HER kinase inhibition in patients with HER2- and HER3-mutant cancers.

Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE Jr, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB.

Nature. 2018 Feb 8;554(7691):189-194. doi: 10.1038/nature25475. Epub 2018 Jan 31.

10.

MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer.

Gawrzak S, Rinaldi L, Gregorio S, Arenas EJ, Salvador F, Urosevic J, Figueras-Puig C, Rojo F, Del Barco Barrantes I, Cejalvo JM, Palafox M, Guiu M, Berenguer-Llergo A, Symeonidi A, Bellmunt A, Kalafatovic D, Arnal-Estapé A, Fernández E, Müllauer B, Groeneveld R, Slobodnyuk K, Stephan-Otto Attolini C, Saura C, Arribas J, Cortes J, Rovira A, Muñoz M, Lluch A, Serra V, Albanell J, Prat A, Nebreda AR, Benitah SA, Gomis RR.

Nat Cell Biol. 2018 Feb;20(2):211-221. doi: 10.1038/s41556-017-0021-z. Epub 2018 Jan 22. Erratum in: Nat Cell Biol. 2018 Apr 19;:.

PMID:
29358704
11.

CRTC1 mediates preferential transcription at neuronal activity-regulated CRE/TATA promoters.

Parra-Damas A, Rubió-Ferrarons L, Shen J, Saura CA.

Sci Rep. 2017 Dec 21;7(1):18004. doi: 10.1038/s41598-017-18215-y.

12.

Proteolytic Processing of Neurexins by Presenilins Sustains Synaptic Vesicle Release.

Servián-Morilla E, Robles-Lanuza E, Sánchez-Hidalgo AC, Camacho-Garcia RJ, Paez-Gomez JA, Mavillard F, Saura CA, Martinez-Mir A, Scholl FG.

J Neurosci. 2018 Jan 24;38(4):901-917. doi: 10.1523/JNEUROSCI.1357-17.2017. Epub 2017 Dec 11.

13.

Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy.

Pistilli B, Pluard T, Urruticoechea A, Farci D, Kong A, Bachelot T, Chan S, Han HS, Jerusalem G, Urban P, Robinson D, Mouhaër SL, Tomaso ED, Massacesi C, Saura C.

Breast Cancer Res Treat. 2018 Apr;168(2):357-364. doi: 10.1007/s10549-017-4596-7. Epub 2017 Dec 2.

PMID:
29198055
14.

Emerging Roles of CREB-Regulated Transcription Coactivators in Brain Physiology and Pathology.

Saura CA, Cardinaux JR.

Trends Neurosci. 2017 Dec;40(12):720-733. doi: 10.1016/j.tins.2017.10.002. Epub 2017 Oct 30. Review.

PMID:
29097017
15.

Suspended Silicon Microphotodiodes for Electrochemical and Biological Applications.

Vargas-Estevez C, Duch M, Duque M, Del Campo FJ, Enriquez-Barreto L, Murillo G, Torras N, Plaza JA, Saura CA, Esteve J.

Small. 2017 Nov;13(41). doi: 10.1002/smll.201701920. Epub 2017 Sep 25.

PMID:
28945947
16.

Receptor-heteromer mediated regulation of endocannabinoid signaling in activated microglia. Role of CB1 and CB2 receptors and relevance for Alzheimer's disease and levodopa-induced dyskinesia.

Navarro G, Borroto-Escuela D, Angelats E, Etayo Í, Reyes-Resina I, Pulido-Salgado M, Rodríguez-Pérez AI, Canela EI, Saura J, Lanciego JL, Labandeira-García JL, Saura CA, Fuxe K, Franco R.

Brain Behav Immun. 2018 Jan;67:139-151. doi: 10.1016/j.bbi.2017.08.015. Epub 2017 Aug 24.

PMID:
28843453
17.

Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

Kim SB, Dent R, Im SA, Espié M, Blau S, Tan AR, Isakoff SJ, Oliveira M, Saura C, Wongchenko MJ, Kapp AV, Chan WY, Singel SM, Maslyar DJ, Baselga J; LOTUS investigators.

Lancet Oncol. 2017 Oct;18(10):1360-1372. doi: 10.1016/S1470-2045(17)30450-3. Epub 2017 Aug 8.

PMID:
28800861
18.

A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors.

Saura C, Roda D, Roselló S, Oliveira M, Macarulla T, Pérez-Fidalgo JA, Morales-Barrera R, Sanchis-García JM, Musib L, Budha N, Zhu J, Nannini M, Chan WY, Sanabria Bohórquez SM, Meng RD, Lin K, Yan Y, Patel P, Baselga J, Tabernero J, Cervantes A.

Cancer Discov. 2017 Jan;7(1):102-113. doi: 10.1158/2159-8290.CD-16-0512. Epub 2016 Nov 21.

19.

CRTC1 Function During Memory Encoding Is Disrupted in Neurodegeneration.

Parra-Damas A, Chen M, Enriquez-Barreto L, Ortega L, Acosta S, Perna JC, Fullana MN, Aguilera J, Rodríguez-Alvarez J, Saura CA.

Biol Psychiatry. 2017 Jan 15;81(2):111-123. doi: 10.1016/j.biopsych.2016.06.025. Epub 2016 Jul 11.

PMID:
27587263
20.

Preservation of cell-survival mechanisms by the presenilin-1 K239N mutation may cause its milder clinical phenotype.

Sarroca S, Molina-Martínez P, Aresté C, Etzrodt M, García de Frutos P, Gasa R, Antonell A, Molinuevo JL, Sánchez-Valle R, Saura CA, Lladó A, Sanfeliu C.

Neurobiol Aging. 2016 Oct;46:169-79. doi: 10.1016/j.neurobiolaging.2016.07.002. Epub 2016 Jul 15.

PMID:
27498054
21.

Menopause status is associated with circadian- and sleep-related alterations.

Gómez-Santos C, Saura CB, Lucas JA, Castell P, Madrid JA, Garaulet M.

Menopause. 2016 Jun;23(6):682-90. doi: 10.1097/GME.0000000000000612.

PMID:
27093617
22.

SEOM clinical guidelines in metastatic breast cancer 2015.

Gavilá J, Lopez-Tarruella S, Saura C, Muñoz M, Oliveira M, De la Cruz-Merino L, Morales S, Alvarez I, Virizuela JA, Martin M.

Clin Transl Oncol. 2015 Dec;17(12):946-55. doi: 10.1007/s12094-015-1476-7. Epub 2015 Dec 18.

23.

Gene expression parallels synaptic excitability and plasticity changes in Alzheimer's disease.

Saura CA, Parra-Damas A, Enriquez-Barreto L.

Front Cell Neurosci. 2015 Aug 25;9:318. doi: 10.3389/fncel.2015.00318. eCollection 2015. Review.

24.

Phase I/II study of pilaralisib (SAR245408) in combination with trastuzumab or trastuzumab plus paclitaxel in trastuzumab-refractory HER2-positive metastatic breast cancer.

Tolaney S, Burris H, Gartner E, Mayer IA, Saura C, Maurer M, Ciruelos E, Garcia AA, Campana F, Wu B, Xu Y, Jiang J, Winer E, Krop I.

Breast Cancer Res Treat. 2015 Jan;149(1):151-61. doi: 10.1007/s10549-014-3248-4. Epub 2014 Dec 24.

PMID:
25537644
25.

Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.

Saura C, Garcia-Saenz JA, Xu B, Harb W, Moroose R, Pluard T, Cortés J, Kiger C, Germa C, Wang K, Martin M, Baselga J, Kim SB.

J Clin Oncol. 2014 Nov 10;32(32):3626-33. doi: 10.1200/JCO.2014.56.3809. Epub 2014 Oct 6.

PMID:
25287822
26.

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.

De Mattos-Arruda L, Weigelt B, Cortes J, Won HH, Ng CK, Nuciforo P, Bidard FC, Aura C, Saura C, Peg V, Piscuoglio S, Oliveira M, Smolders Y, Patel P, Norton L, Tabernero J, Berger MF, Seoane J, Reis-Filho JS.

Ann Oncol. 2014 Sep;25(9):1729-35. doi: 10.1093/annonc/mdu239. Epub 2014 Jul 9.

PMID:
25009010
27.

Phase I trial of olaparib in combination with cisplatin for the treatment of patients with advanced breast, ovarian and other solid tumors.

Balmaña J, Tung NM, Isakoff SJ, Graña B, Ryan PD, Saura C, Lowe ES, Frewer P, Winer E, Baselga J, Garber JE.

Ann Oncol. 2014 Aug;25(8):1656-63. doi: 10.1093/annonc/mdu187. Epub 2014 May 14.

PMID:
24827126
28.

Crtc1 activates a transcriptional program deregulated at early Alzheimer's disease-related stages.

Parra-Damas A, Valero J, Chen M, España J, Martín E, Ferrer I, Rodríguez-Alvarez J, Saura CA.

J Neurosci. 2014 Apr 23;34(17):5776-87. doi: 10.1523/JNEUROSCI.5288-13.2014.

29.

Ras protein activation is a key event in activity-dependent survival of cerebellar granule neurons.

Xifró X, Miñano-Molina AJ, Saura CA, Rodríguez-Álvarez J.

J Biol Chem. 2014 Mar 21;289(12):8462-72. doi: 10.1074/jbc.M113.536375. Epub 2014 Feb 12.

30.

Phase Ib study of Buparlisib plus Trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy.

Saura C, Bendell J, Jerusalem G, Su S, Ru Q, De Buck S, Mills D, Ruquet S, Bosch A, Urruticoechea A, Beck JT, Di Tomaso E, Sternberg DW, Massacesi C, Hirawat S, Dirix L, Baselga J.

Clin Cancer Res. 2014 Apr 1;20(7):1935-45. doi: 10.1158/1078-0432.CCR-13-1070. Epub 2014 Jan 27.

31.

ApoER2 processing by presenilin-1 modulates reelin expression.

Balmaceda V, Cuchillo-Ibáñez I, Pujadas L, García-Ayllón MS, Saura CA, Nimpf J, Soriano E, Sáez-Valero J.

FASEB J. 2014 Apr;28(4):1543-54. doi: 10.1096/fj.13-239350. Epub 2013 Dec 16.

PMID:
24344333
32.

CSF Presenilin-1 complexes are increased in Alzheimer's disease.

García-Ayllón MS, Campanari ML, Brinkmalm G, Rábano A, Alom J, Saura CA, Andreasen N, Blennow K, Sáez-Valero J.

Acta Neuropathol Commun. 2013 Aug 6;1:46. doi: 10.1186/2051-5960-1-46.

33.

Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068.

Yan Y, Serra V, Prudkin L, Scaltriti M, Murli S, Rodríguez O, Guzman M, Sampath D, Nannini M, Xiao Y, Wagle MC, Wu JQ, Wongchenko M, Hampton G, Ramakrishnan V, Lackner MR, Saura C, Roda D, Cervantes A, Tabernero J, Patel P, Baselga J.

Clin Cancer Res. 2013 Dec 15;19(24):6976-86. doi: 10.1158/1078-0432.CCR-13-0978. Epub 2013 Oct 18.

34.

X-linked inhibitor of apoptosis protein negatively regulates neuronal differentiation through interaction with cRAF and Trk.

Fadó R, Moubarak RS, Miñano-Molina AJ, Barneda-Zahonero B, Valero J, Saura CA, Moran J, Comella JX, Rodríguez-Álvarez J.

Sci Rep. 2013;3:2397. doi: 10.1038/srep02397.

35.

Neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early stage breast cancer and evaluation of βIII-tubulin expression as a predictive marker.

Saura C, Tseng LM, Chan S, Chacko RT, Campone M, Manikhas A, Nag SM, Leichman CG, Dasappa L, Fasching PA, Hurtado de Mendoza F, Symmans WF, Liu D, Mukhopadhyay P, Horak C, Xing G, Pusztai L.

Oncologist. 2013;18(7):787-94. doi: 10.1634/theoncologist.2013-0075. Epub 2013 Jul 12.

36.

First cases of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infections in France, investigations and implications for the prevention of human-to-human transmission, France, May 2013.

Mailles A, Blanckaert K, Chaud P, van der Werf S, Lina B, Caro V, Campese C, Guéry B, Prouvost H, Lemaire X, Paty MC, Haeghebaert S, Antoine D, Ettahar N, Noel H, Behillil S, Hendricx S, Manuguerra JC, Enouf V, La Ruche G, Semaille C, Coignard B, Lévy-Bruhl D, Weber F, Saura C, Che D; investigation team.

Euro Surveill. 2013 Jun 13;18(24). pii: 20502.

37.

A multicenter trial evaluating retaspimycin HCL (IPI-504) plus trastuzumab in patients with advanced or metastatic HER2-positive breast cancer.

Modi S, Saura C, Henderson C, Lin NU, Mahtani R, Goddard J, Rodenas E, Hudis C, O'Shaughnessy J, Baselga J.

Breast Cancer Res Treat. 2013 May;139(1):107-13. doi: 10.1007/s10549-013-2510-5. Epub 2013 Apr 12.

38.

Biomarker analysis of neoadjuvant doxorubicin/cyclophosphamide followed by ixabepilone or Paclitaxel in early-stage breast cancer.

Horak CE, Pusztai L, Xing G, Trifan OC, Saura C, Tseng LM, Chan S, Welcher R, Liu D.

Clin Cancer Res. 2013 Mar 15;19(6):1587-95. doi: 10.1158/1078-0432.CCR-12-1359. Epub 2013 Jan 22.

39.

Management of the axilla in early breast cancer patients in the genomic era.

Oliveira M, Cortés J, Bellet M, Balmaña J, De Mattos-Arruda L, Gómez P, Muñoz E, Ortega V, Pérez J, Saura C, Vidal M, Rubio IT, Di Cosimo S.

Ann Oncol. 2013 May;24(5):1163-70. doi: 10.1093/annonc/mds592. Epub 2012 Nov 19. Review.

PMID:
23165977
40.

Implication of breast cancer phenotype for patients with leptomeningeal carcinomatosis.

Torrejón D, Oliveira M, Cortes J, Sanchez-Olle G, Gómez P, Bellet M, Saura C, Peg V, Rovira A, Di Cosimo S.

Breast. 2013 Feb;22(1):19-23. doi: 10.1016/j.breast.2012.10.009. Epub 2012 Nov 6.

PMID:
23137566
41.

Multidisciplinary approach to breast cancer diagnosed during pregnancy: maternal and neonatal outcomes.

Córdoba O, Llurba E, Saura C, Rubio I, Ferrer Q, Cortés J, Xercavins J.

Breast. 2013 Aug;22(4):515-9. doi: 10.1016/j.breast.2012.10.005. Epub 2012 Oct 30.

PMID:
23116970
42.

Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials.

Dienstmann R, Serpico D, Rodon J, Saura C, Macarulla T, Elez E, Alsina M, Capdevila J, Perez-Garcia J, Sánchez-Ollé G, Aura C, Prudkin L, Landolfi S, Hernández-Losa J, Vivancos A, Tabernero J.

Mol Cancer Ther. 2012 Sep;11(9):2062-71. doi: 10.1158/1535-7163.MCT-12-0290. Epub 2012 Jun 21.

43.

ATP and noradrenaline activate CREB in astrocytes via noncanonical Ca(2+) and cyclic AMP independent pathways.

Carriba P, Pardo L, Parra-Damas A, Lichtenstein MP, Saura CA, Pujol A, Masgrau R, Galea E.

Glia. 2012 Sep;60(9):1330-44. doi: 10.1002/glia.22352. Epub 2012 May 16.

PMID:
22593004
44.

Molecular prescreening to select patient population in early clinical trials.

Rodón J, Saura C, Dienstmann R, Vivancos A, Ramón y Cajal S, Baselga J, Tabernero J.

Nat Rev Clin Oncol. 2012 Apr 3;9(6):359-66. doi: 10.1038/nrclinonc.2012.48. Review.

PMID:
22473105
45.

Nurr1 protein is required for N-methyl-D-aspartic acid (NMDA) receptor-mediated neuronal survival.

Barneda-Zahonero B, Servitja JM, Badiola N, Miñano-Molina AJ, Fadó R, Saura CA, Rodríguez-Alvarez J.

J Biol Chem. 2012 Mar 30;287(14):11351-62. doi: 10.1074/jbc.M111.272427. Epub 2012 Jan 31.

46.

CREB-regulated transcription coactivator 1-dependent transcription in Alzheimer's disease mice.

Saura CA.

Neurodegener Dis. 2012;10(1-4):250-2. doi: 10.1159/000333341. Epub 2012 Jan 6.

PMID:
22236576
47.

Long-term memory deficits in Huntington's disease are associated with reduced CBP histone acetylase activity.

Giralt A, Puigdellívol M, Carretón O, Paoletti P, Valero J, Parra-Damas A, Saura CA, Alberch J, Ginés S.

Hum Mol Genet. 2012 Mar 15;21(6):1203-16. doi: 10.1093/hmg/ddr552. Epub 2011 Nov 24.

PMID:
22116937
48.

Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis.

Cortes J, Calvo V, Ramírez-Merino N, O'Shaughnessy J, Brufsky A, Robert N, Vidal M, Muñoz E, Perez J, Dawood S, Saura C, Di Cosimo S, González-Martín A, Bellet M, Silva OE, Miles D, Llombart A, Baselga J.

Ann Oncol. 2012 May;23(5):1130-7. doi: 10.1093/annonc/mdr432. Epub 2011 Oct 4. Review.

PMID:
21976387
49.

Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors.

Serrano C, Cortés J, De Mattos-Arruda L, Bellet M, Gómez P, Saura C, Pérez J, Vidal M, Muñoz-Couselo E, Carreras MJ, Sánchez-Ollé G, Tabernero J, Baselga J, Di Cosimo S.

Ann Oncol. 2012 Apr;23(4):897-902. doi: 10.1093/annonc/mdr348. Epub 2011 Aug 9.

PMID:
21828361
50.

Deferral from donating blood of men who have sex with men: impact on the risk of HIV transmission by transfusion in France.

Pillonel J, Heraud-Bousquet V, Pelletier B, Semaille C, Velter A, Saura C, Desenclos JC, Danic B; Blood Donor Epidemiological Surveillance Study Group.

Vox Sang. 2012 Jan;102(1):13-21. doi: 10.1111/j.1423-0410.2011.01509.x. Epub 2011 Jun 21.

PMID:
21692806

Supplemental Content

Support Center